Clinical Trial Update: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating sunvozertinib in combination with chemotherapy for EGFR-mutant NSCLC after EGFR-TKI failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Sichuan University | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN